GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...
The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback